CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Zimmer Biomet Holdings - ZBH CFD

123.91
0.11%
Market Trading Hours* (UTC) Opens on Monday at 14:30

Mon - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading сonditions
Spread 0.25
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Zimmer Biomet Holdings Inc ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 124.05
Open* 123.37
1-Year Change* -0.32%
Day's Range* 123.37 - 124.78
52 wk Range 102.00-149.25
Average Volume (10 days) 1.73M
Average Volume (3 months) 36.10M
Market Cap 25.88B
P/E Ratio 54.89
Shares Outstanding 208.98M
Revenue 7.28B
EPS 2.26
Dividend (Yield %) 0.77526
Beta 1.04
Next Earnings Date Feb 8, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 1, 2024 123.91 0.93 0.76% 122.98 124.85 122.95
Feb 29, 2024 124.05 1.08 0.88% 122.97 124.60 122.77
Feb 28, 2024 124.03 -1.54 -1.23% 125.57 125.81 123.47
Feb 27, 2024 126.30 0.64 0.51% 125.66 126.89 125.66
Feb 26, 2024 126.82 -1.50 -1.17% 128.32 128.92 126.76
Feb 23, 2024 129.06 1.59 1.25% 127.47 129.40 127.46
Feb 22, 2024 128.44 0.86 0.67% 127.58 129.04 126.45
Feb 21, 2024 128.28 4.23 3.41% 124.05 128.76 124.05
Feb 20, 2024 124.90 0.76 0.61% 124.14 125.77 122.59
Feb 16, 2024 124.59 0.59 0.48% 124.00 125.88 123.90
Feb 15, 2024 124.25 2.31 1.89% 121.94 124.43 121.56
Feb 14, 2024 121.69 -0.82 -0.67% 122.51 123.79 121.37
Feb 13, 2024 123.06 -1.36 -1.09% 124.42 125.49 122.12
Feb 12, 2024 125.74 3.86 3.17% 121.88 125.96 121.78
Feb 9, 2024 122.42 -1.05 -0.85% 123.47 125.17 120.96
Feb 8, 2024 122.72 3.77 3.17% 118.95 124.02 118.95
Feb 7, 2024 127.22 -0.17 -0.13% 127.39 128.38 126.76
Feb 6, 2024 127.50 2.45 1.96% 125.05 127.55 125.05
Feb 5, 2024 125.25 0.25 0.20% 125.00 126.69 124.96
Feb 2, 2024 126.24 0.74 0.59% 125.50 126.96 125.34

Zimmer Biomet Holdings Events

Time (UTC) Country Event
Tuesday, April 30, 2024

Time (UTC)

10:30

Country

US

Event

Q1 2024 Zimmer Biomet Holdings Inc Earnings Release
Q1 2024 Zimmer Biomet Holdings Inc Earnings Release

Forecast

-

Previous

-
Friday, May 10, 2024

Time (UTC)

12:00

Country

US

Event

Zimmer Biomet Holdings Inc Annual Shareholders Meeting
Zimmer Biomet Holdings Inc Annual Shareholders Meeting

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 6939.9 6827.3 6127.5 7982.2 7932.9
Revenue 6939.9 6827.3 6127.5 7982.2 7932.9
Cost of Revenue, Total 2019.5 1960.4 1824.3 2252.6 2271.9
Gross Profit 4920.4 4866.9 4303.2 5729.6 5661
Total Operating Expense 6243.6 6132.1 6044.4 6844.7 7899.1
Selling/General/Admin. Expenses, Total 2761.7 2843.4 2712.7 3343.8 3379.3
Research & Development 406 435.8 322.8 449.3 391.7
Depreciation / Amortization 526.8 529.5 512.1 584.3 595.9
Unusual Expense (Income) 529.6 363 672.5 214.7 1260.3
Operating Income 696.3 695.2 83.1 1137.5 33.8
Interest Income (Expense), Net Non-Operating -164.8 -208.4 -212.1 -237.9 -264.6
Other, Net -128 12.2 23.8 6.2 -40.3
Net Income Before Taxes 403.5 499 -105.2 905.8 -271.1
Net Income After Taxes 291.2 445.5 -9.2 816.5 -371
Minority Interest -1 -0.5 -1.5 0.1 0.1
Net Income Before Extra. Items 290.2 445 -10.7 816.6 -370.9
Net Income 231.4 401.6 -138.9 1131.6 -379.2
Income Available to Common Excl. Extra. Items 290.2 445 -10.7 816.6 -370.9
Income Available to Common Incl. Extra. Items 231.4 401.6 -138.9 1131.6 -379.2
Diluted Net Income 231.4 401.6 -138.9 1131.6 -379.2
Diluted Weighted Average Shares 210.3 210.4 207 206.7 203.5
Diluted EPS Excluding Extraordinary Items 1.37993 2.11502 -0.05169 3.95065 -1.8226
Dividends per Share - Common Stock Primary Issue 0.96 0.96 0.96 0.96 0.96
Diluted Normalized EPS 3.19736 3.65533 2.06002 5.72252 2.79703
Total Extraordinary Items -58.8 -43.4 -128.2 315 -8.3
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 1869.6 1831 1825.1 1669.8 1781.8
Revenue 1869.6 1831 1825.1 1669.8 1781.8
Cost of Revenue, Total 525.5 500.8 520.3 488.2 511
Gross Profit 1344.1 1330.2 1304.8 1181.6 1270.8
Total Operating Expense 1540 1503.7 1853.4 1424.5 1500.9
Selling/General/Admin. Expenses, Total 725.8 715.9 727.1 654.9 695.2
Research & Development 118.1 110.4 108 101.7 99.4
Depreciation / Amortization 138.2 133.4 131.5 131.5 133
Unusual Expense (Income) 32.3 43.1 366.5 48.2 62.3
Operating Income 329.6 327.3 -28.3 245.3 280.9
Interest Income (Expense), Net Non-Operating -51.6 -48.2 -42.6 -42.3 -38.8
Other, Net -1.2 7.7 -3.9 -25.4 -42.6
Net Income Before Taxes 276.8 286.8 -74.8 177.6 199.5
Net Income After Taxes 209.9 232.7 -130.2 194.2 154
Minority Interest -0.2 -0.2 -0.3 -0.2 -0.3
Net Income Before Extra. Items 209.7 232.5 -130.5 194 153.7
Total Extraordinary Items 0 0 0 0 0
Net Income 209.7 232.5 -130.5 194 153.7
Income Available to Common Excl. Extra. Items 209.5 232.5 -130.5 194 153.7
Income Available to Common Incl. Extra. Items 209.5 232.5 -130.5 194 153.7
Diluted Net Income 209.5 232.5 -130.5 194 153.7
Diluted Weighted Average Shares 209.9 210.4 209.9 210.3 210.3
Diluted EPS Excluding Extraordinary Items 0.99809 1.10504 -0.62172 0.92249 0.73086
Dividends per Share - Common Stock Primary Issue 0.24 0.24 0.24 0.24 0.24
Diluted Normalized EPS 1.11479 1.27124 0.51322 1.07147 0.95954
Other Operating Expenses, Total 0.1 0.1
Total Adjustments to Net Income -0.2
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 4427.3 4885 5083.3 4723.9 4427.4
Cash and Short Term Investments 375.7 478.5 802.1 617.9 542.8
Cash & Equivalents 375.7 478.5 802.1 617.9 542.8
Short Term Investments
Total Receivables, Net 1381.5 1404.9 1452.7 1363.9 1275.8
Accounts Receivable - Trade, Net 1381.5 1404.9 1452.7 1363.9 1275.8
Total Inventory 2147.2 2394.5 2450.7 2385 2256.5
Prepaid Expenses 522.9 607.1 377.8 315.3 314.4
Other Current Assets, Total 0 41.8 37.9
Total Assets 21066 23456.4 24417.7 24638.7 24126.8
Property/Plant/Equipment, Total - Net 2068.9 2287.7 2322.2 2344.1 2015.4
Property/Plant/Equipment, Total - Gross 6654.8 7006.8 6599.4 6183.5 5437.1
Accumulated Depreciation, Total -4585.9 -4719.1 -4277.2 -3839.4 -3421.7
Goodwill, Net 8580.2 9192.2 9261.8 9599.7 9594.4
Intangibles, Net 5063.8 6299.8 7055.5 7257.6 7684.6
Other Long Term Assets, Total 925.8 791.7 694.9 713.4 405
Total Current Liabilities 2358.2 3467.9 2556.9 3441.5 2421.3
Accounts Payable 354.1 351.2 330 400.9 362.6
Accrued Expenses 971.5 1161.6 1284.5 1156.4 930.9
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 544.3 1605.1 500 1500 525
Other Current Liabilities, Total 488.3 350 442.4 384.2 602.8
Total Liabilities 9045.7 10795.7 12223.5 12250.6 12855.5
Total Long Term Debt 5152.2 5463.7 7626.5 6715 8399.1
Long Term Debt 5152.2 5463.7 7626.5 6715 8399.1
Deferred Income Tax 474.8 665.6 790.4 840.1 999.5
Minority Interest 6.7 5.7 5.2 4.7 4.8
Other Liabilities, Total 1053.8 1192.8 1244.5 1249.3 1030.8
Total Equity 12020.3 12660.7 12194.2 12388.1 11271.3
Common Stock 3.1 3.1 3.1 3.1 3.1
Additional Paid-In Capital 9504.4 9314.8 9121.6 8920.1 8686.1
Retained Earnings (Accumulated Deficit) 9559.3 10292.2 10086.9 10427.3 9491.2
Treasury Stock - Common -6867.2 -6717.8 -6719.6 -6720.5 -6721.7
Unrealized Gain (Loss)
Other Equity, Total -179.3 -231.6 -297.8 -241.9 -187.4
Total Liabilities & Shareholders’ Equity 21066 23456.4 24417.7 24638.7 24126.8
Total Common Shares Outstanding 209 209 207.6 206 204
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 4372 4387.9 4411.9 4427.3 4534.4
Cash and Short Term Investments 292.1 319.8 330.2 375.7 545.4
Cash & Equivalents 292.1 319.8 330.2 375.7 545.4
Total Receivables, Net 1340.7 1367.3 1380.9 1381.5 1278.5
Accounts Receivable - Trade, Net 1340.7 1367.3 1380.9 1381.5 1278.5
Total Inventory 2323.3 2275.8 2241.3 2147.2 2128.6
Prepaid Expenses 415.8 425.1 459.5 522.9 581.9
Total Assets 21217.3 21294.3 21243.5 21066 21333.3
Property/Plant/Equipment, Total - Net 2032.2 1975 1906.4 1872.5 1801.6
Property/Plant/Equipment, Total - Gross 6646.6 6717.3 6593.9 6458.4 6344.4
Accumulated Depreciation, Total -4614.4 -4742.3 -4687.5 -4585.9 -4542.8
Goodwill, Net 8710.4 8743.7 8734.9 8580.2 8798.8
Intangibles, Net 4891.7 5027.7 5071.7 5063.8 5136.5
Other Long Term Assets, Total 1211 1160 1118.6 1122.2 1062
Total Current Liabilities 2071.5 2233.7 2335.9 2358.2 2295.7
Accounts Payable 319.7 354.6 397.1 354.1 333.9
Accrued Expenses 234.2 336.2 115.9
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 355 520 585 544.3 659.1
Other Current Liabilities, Total 1396.8 1359.1 1119.6 1123.6 1186.8
Total Liabilities 8706.5 8922.8 9092.8 9045.7 9088.6
Total Long Term Debt 5127.4 5189.4 5204.8 5152.2 5055.2
Long Term Debt 5127.4 5189.4 5204.8 5152.2 5055.2
Deferred Income Tax 465.4 474.9 484.6 474.8 541.3
Minority Interest 7.2 7.1 6.9 6.7 6.4
Other Liabilities, Total 1035 1017.7 1060.6 1053.8 1190
Total Equity 12510.8 12371.5 12150.7 12020.3 12244.7
Common Stock 3.2 3.2 3.2 3.1 3.1
Additional Paid-In Capital 9801.4 9766 9692.4 9504.4 9463.9
Retained Earnings (Accumulated Deficit) 10014.9 9902.3 9741.7 9559.3 9739.9
Treasury Stock - Common -7122.2 -7122.2 -7108.6 -6867.2 -6717.3
Other Equity, Total -186.5 -177.8 -178 -179.3 -244.9
Total Liabilities & Shareholders’ Equity 21217.3 21294.3 21243.5 21066 21333.3
Total Common Shares Outstanding 209 208.8 208.5 209 209.8
Other Current Assets, Total 0.1 -0.1 0
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line 291.2 445.5 -9.2 1131.5 -379.3
Cash From Operating Activities 1284.7 1499.2 1204.5 1585.8 1747.4
Cash From Operating Activities 926.4 937.7 898.4 1006.1 1040.5
Deferred Taxes -64.4 -102.1 39.4 -538.7 13.4
Non-Cash Items 442.9 352.3 705.7 154.4 1045.2
Cash Taxes Paid 326.6 258.4 142 192.5 237.1
Changes in Working Capital -311.4 -134.2 -429.8 -167.5 27.6
Cash From Investing Activities -529.2 -503.6 -613.8 -729.3 -416.6
Capital Expenditures -446.2 -417.2 -370.9 -720.6 -439
Other Investing Cash Flow Items, Total -83 -86.4 -242.9 -8.7 22.4
Cash From Financing Activities -843.8 -1306 -421.8 -779.9 -1302.2
Financing Cash Flow Items 466.4 -173.4 -100.2 -25.3 -60.5
Total Cash Dividends Paid -201.2 -200.1 -198.5 -196.7 -195.2
Issuance (Retirement) of Stock, Net -48.3 122.5 129.8 158.2 107.9
Issuance (Retirement) of Debt, Net -1060.7 -1055 -252.9 -716.1 -1154.4
Foreign Exchange Effects -14.5 -13.2 15.3 -1.5 -10.2
Net Change in Cash -102.8 -323.6 184.2 75.1 18.4
Cash Interest Paid 161.7 219 193.1 226.9 282.8
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line 232.8 291.2 421.4 227.2 73.2
Cash From Operating Activities 307.7 1284.7 1040.5 589.7 237.2
Cash From Operating Activities 231.8 926.4 697.9 466.5 233.8
Non-Cash Items 22.5 442.9 9.7 -17.7 -55.3
Changes in Working Capital -179.4 -311.4 -88.5 -86.3 -14.5
Cash From Investing Activities -149.4 -529.2 -416.7 -331.5 -88.3
Capital Expenditures -129.5 -446.2 -316.7 -197.9 -92.8
Other Investing Cash Flow Items, Total -19.9 -83 -100 -133.6 4.5
Cash From Financing Activities -206.7 -843.8 -530.4 -336.5 -190.5
Financing Cash Flow Items -14.6 466.4 467.1 469 469.2
Total Cash Dividends Paid -50.3 -201.2 -150.8 -100.5 -50.2
Issuance (Retirement) of Stock, Net -231.6 -48.3 63.2 45 40.5
Issuance (Retirement) of Debt, Net 89.8 -1060.7 -909.9 -750 -650
Foreign Exchange Effects 2.9 -14.5 -26.5 -13.8 -1.1
Net Change in Cash -45.5 -102.8 66.9 -92.1 -42.7
Deferred Taxes -64.4
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 11.5042 24039661 -225675 2023-06-30 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 5.583 11666511 484099 2023-06-30 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 4.3342 9056896 318082 2023-06-30 LOW
T. Rowe Price Associates, Inc. Investment Advisor 4.2784 8940284 -1206323 2023-06-30 LOW
Invesco Advisers, Inc. Investment Advisor 2.4081 5032041 943637 2023-06-30 LOW
Dodge & Cox Investment Advisor/Hedge Fund 2.3279 4864500 -57250 2023-06-30 LOW
PRIMECAP Management Company Investment Advisor 2.3271 4862792 -72120 2023-06-30
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 2.1121 4413445 98278 2023-06-30 LOW
American Century Investment Management, Inc. Investment Advisor/Hedge Fund 1.9197 4011555 -1043640 2023-06-30 LOW
BlackRock Financial Management, Inc. Investment Advisor/Hedge Fund 1.7401 3636143 -608827 2023-06-30 LOW
Templeton Investment Counsel, L.L.C. Investment Advisor/Hedge Fund 1.6517 3451411 -177903 2023-06-30 LOW
JP Morgan Asset Management Investment Advisor 1.4563 3043231 -233760 2023-06-30 LOW
Victory Capital Management Inc. Investment Advisor/Hedge Fund 1.4052 2936316 -5667 2023-06-30 LOW
Neuberger Berman, LLC Investment Advisor/Hedge Fund 1.2679 2649387 24855 2023-06-30 LOW
Allspring Global Investments, LLC Investment Advisor/Hedge Fund 1.1361 2374002 222999 2023-09-30 LOW
Capital Research Global Investors Investment Advisor 1.1286 2358454 100139 2023-06-30 LOW
Boston Partners Investment Advisor/Hedge Fund 0.9982 2085873 -180000 2023-06-30 LOW
BlackRock Asset Management Ireland Limited Investment Advisor 0.9299 1943260 856427 2023-06-30 LOW
Van Eck Associates Corporation Investment Advisor/Hedge Fund 0.9263 1935708 344858 2023-06-30 LOW
Legal & General Investment Management Ltd. Investment Advisor/Hedge Fund 0.9112 1903994 219309 2023-06-30 LOW

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Zimmer Company profile

About Zimmer Biomet Holdings Inc

Zimmer Biomet Holdings, Inc. is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products. The Company's products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. The Company manages its operations through three geographic operating segments: the Americas and Global Businesses, consisting principally of the United States and other North, Central and South American markets; Europe, Middle East and Africa (EMEA), consisting principally of France, Germany, Italy, Spain and the United Kingdom, and Asia Pacific, consisting primarily of Japan, China, Australia, New Zealand, Korea, Taiwan, India, Thailand, Singapore, Hong Kong and Malaysia.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Zimmer Biomet Holdings Inc revenues increased 12% to $7.84B. Net income before extraordinary items totaled $431.7M vs. loss of $143.9M. Revenues reflect Americas Orthopedics segment increase of 11% to $4.1B, EMEA segment increase of 19% to $1.53B, Americas Spine and Global Dental segment increase of 13% to $882M, Americas segment increase of 11% to $4.8B, EMEA segment increase of 20% to $1.67B.

Equity composition

Common Stock $.01 Par, 03/11, 1B auth., 255,200,000 issd. less 63,200,000 shs. in Treas. @ $3.78B.Insider owns 0.13%.

Industry: Medical Equipment, Supplies & Distribution (NEC)

345 E Main St
WARSAW
INDIANA 46580-2746
US

Income Statement

  • Annual
  • Quarterly

News

Facade on the Federal Reserve Building in Washington DC

Central Banks: which one will cut first?

Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut

18:44, 1 March 2024

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

UK Bank Earnings: What to expect from Lloyds, Barclays and HSBC?

UK banks will be in the spotlight in the week ahead as the European earnings season continues

16:38, 16 February 2024

Is Big Tech behind the apparent bull market rally?

While the Magnificent Seven have dominated market momentum in recent months, it’s not true that they are the sole drivers of the recent rally in equity markets.

16:05, 8 February 2024

US Earnings Week Ahead: Walt Disney, Uber, and Pepsi Co.

The last of the Magnificent Seven have reported, delivering mixed results. Meanwhile, according to FactSet, the S&P 500 is set for negative earnings growth for Q4, with estimates for the next quarter also downgraded.

16:24, 2 February 2024

Bank of England preview: will updated projections show more cuts are expected in 2024?

Markets have no doubt that the BoE will keep its rate unchanged

15:43, 31 January 2024

Meta Platforms Q4 earnings forecast to surge on solid ad revenues

Meta Platforms (META) reports its Q4 results after Wall Street’s closing bell on February 1, 2024. We preview what to expect from the results and analyse the stock’s technicals.

15:33, 31 January 2024

People also watch

XRP/USD

0.63 Price
-2.270% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

BTC/USD

61,825.20 Price
-0.320% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

US100

18,286.90 Price
+1.410% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 7.0

Oil - Crude

79.49 Price
+1.850% 1D Chg, %
Long position overnight fee 0.0266%
Short position overnight fee -0.0485%
Overnight fee time 22:00 (UTC)
Spread 0.030

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading